Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05061940 · ClinicalTrials.gov registry record
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
A clinical trial, sponsored by Repertoire Immune Medicines.
- Terminated
- Registry status
- 22
- Enrollment target
NCT05061940 is a clinical trial that was terminated before completion, run by Repertoire Immune Medicines. The registered enrollment target is 22 participants.
The verdict
NCT05061940 was terminated before completion, sponsored by Repertoire Immune Medicines.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
Interventions
- DIAGNOSTIC_TEST Tumor Profiling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2022-10-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05061940
The ClinicalTrials.gov registry entry for NCT05061940 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repertoire Immune Medicines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor Profiling is the first listed.
NCT05061940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05061940 about?
NCT05061940 is a clinical study titled "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.". The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient suitability for a Repertoire Immune Medicines Treatment Protocol.
What is the current status of trial NCT05061940?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2021-05-05. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT05061940?
The interventions under investigation include: Tumor Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05061940?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.